JP2017505622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505622A5 JP2017505622A5 JP2016549322A JP2016549322A JP2017505622A5 JP 2017505622 A5 JP2017505622 A5 JP 2017505622A5 JP 2016549322 A JP2016549322 A JP 2016549322A JP 2016549322 A JP2016549322 A JP 2016549322A JP 2017505622 A5 JP2017505622 A5 JP 2017505622A5
- Authority
- JP
- Japan
- Prior art keywords
- baff
- seq
- antibody molecule
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 8
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 claims 3
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000050326 human TNFSF13B Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108010072220 Cyclophilin A Proteins 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934124P | 2014-01-31 | 2014-01-31 | |
| US61/934,124 | 2014-01-31 | ||
| PCT/US2015/013711 WO2016039801A1 (en) | 2014-01-31 | 2015-01-30 | Novel anti-baff antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505622A JP2017505622A (ja) | 2017-02-23 |
| JP2017505622A5 true JP2017505622A5 (cg-RX-API-DMAC7.html) | 2018-03-08 |
| JP6511459B2 JP6511459B2 (ja) | 2019-05-15 |
Family
ID=53754266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549322A Active JP6511459B2 (ja) | 2014-01-31 | 2015-01-30 | 新規な抗ｂａｆｆ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9840543B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3099715B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6511459B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160113715A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105873949B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015315834B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016014731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2934965A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2016001742A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA033604B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL246113B (cg-RX-API-DMAC7.html) |
| MX (1) | MX367661B (cg-RX-API-DMAC7.html) |
| PH (1) | PH12016501366A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016039801A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| BR112016014731A2 (pt) | 2014-01-31 | 2017-09-19 | Boehringer Ingelheim Int | Anticorpos anti-baff |
| KR102644875B1 (ko) * | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| WO2017223534A2 (en) * | 2016-06-24 | 2017-12-28 | Anthera Pharmaceuticals, Inc. | Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor |
| US20210347873A1 (en) * | 2016-07-06 | 2021-11-11 | Shanghai Pharmaexplorer Co., Ltd. | Blys antibody, preparation method therefor and application thereof |
| US10869522B2 (en) | 2016-11-04 | 2020-12-22 | Totes Isotoner Corporation | Footwear, and methods of preparing same |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2019136311A2 (en) * | 2018-01-05 | 2019-07-11 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| JP2021521110A (ja) | 2018-04-06 | 2021-08-26 | エータイアー ファーマ， インコーポレイテッド | 抗ｎｒｐ２抗体を含む組成物及び方法 |
| WO2019210168A1 (en) * | 2018-04-26 | 2019-10-31 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| US11807687B2 (en) | 2019-10-03 | 2023-11-07 | Atyr Pharma, Inc. | Therapeutic compositions comprising anti-NRP2 antibodies |
| WO2021188631A1 (en) * | 2020-03-18 | 2021-09-23 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CA3199839A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| CN112516303A (zh) * | 2020-11-18 | 2021-03-19 | 华中科技大学同济医学院附属协和医院 | Baff抗体在制备脓毒血症药物中的应用 |
| CN116178530A (zh) * | 2021-09-26 | 2023-05-30 | 上海君实生物医药科技股份有限公司 | 抗体在治疗SARS-CoV-2感染的用途 |
| CN118440195B (zh) * | 2022-06-17 | 2025-04-08 | 东莞市朋志生物科技有限公司 | 抗脂联素抗体、检测脂联素的试剂和试剂盒 |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| WO2025125137A1 (en) * | 2023-12-11 | 2025-06-19 | Glaxosmithkline Intellectual Property Development Limited | Baff specific antibodies |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| EA006108B1 (ru) | 1999-01-25 | 2005-08-25 | Байоджен, Инк. | Способы стимуляции и ингибирования роста в-клеток, продуцирования иммуноглобулинов и коррекции нарушений, связанных с baff-лигандом, у животного |
| NZ522700A (en) * | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP1826218B1 (en) * | 2004-08-31 | 2014-01-01 | Kowa Company, Ltd. | Antihuman baff antibody |
| WO2006031718A2 (en) | 2004-09-15 | 2006-03-23 | The Uab Research Foundation | Compositions and methods for modulating rank activities |
| EP1801231B1 (en) | 2004-09-15 | 2011-11-30 | Kowa Co., Ltd. | Method of screening baff suppressor or inhibitor |
| WO2007014390A2 (en) * | 2005-07-28 | 2007-02-01 | Biogen Idec Ma Inc. | Methods of targeting baff |
| US8617545B2 (en) | 2005-10-13 | 2013-12-31 | Biogen Idec Ma Inc. | Methods for use with BAFF antagonists |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| PL2315780T3 (pl) | 2008-07-17 | 2016-01-29 | Novartis Ag | Kompozycje i sposoby zastosowania przeciwciał terapeutycznych |
| US20130028897A1 (en) * | 2009-04-27 | 2013-01-31 | Ali Naji | Methods for reducing the level of alloantibodies in a subject |
| WO2011031835A1 (en) | 2009-09-09 | 2011-03-17 | The Uab Research Foundation | Chimeric dr5 polypeptides and uses thereof |
| CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
| CN102918061B (zh) * | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2853731C (en) | 2011-10-28 | 2021-05-18 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| BR112016014731A2 (pt) * | 2014-01-31 | 2017-09-19 | Boehringer Ingelheim Int | Anticorpos anti-baff |
-
2015
- 2015-01-30 BR BR112016014731A patent/BR112016014731A2/pt not_active Application Discontinuation
- 2015-01-30 AU AU2015315834A patent/AU2015315834B2/en not_active Ceased
- 2015-01-30 JP JP2016549322A patent/JP6511459B2/ja active Active
- 2015-01-30 CA CA2934965A patent/CA2934965A1/en not_active Abandoned
- 2015-01-30 EA EA201691541A patent/EA033604B1/ru not_active IP Right Cessation
- 2015-01-30 CN CN201580003487.1A patent/CN105873949B/zh active Active
- 2015-01-30 MX MX2016009877A patent/MX367661B/es active IP Right Grant
- 2015-01-30 EP EP15703426.5A patent/EP3099715B1/en active Active
- 2015-01-30 US US14/609,756 patent/US9840543B2/en active Active
- 2015-01-30 KR KR1020167023947A patent/KR20160113715A/ko not_active Withdrawn
- 2015-01-30 WO PCT/US2015/013711 patent/WO2016039801A1/en not_active Ceased
-
2016
- 2016-06-08 IL IL246113A patent/IL246113B/en not_active IP Right Cessation
- 2016-07-07 CL CL2016001742A patent/CL2016001742A1/es unknown
- 2016-07-11 PH PH12016501366A patent/PH12016501366A1/en unknown
-
2017
- 2017-11-06 US US15/803,993 patent/US10377804B2/en active Active
-
2019
- 2019-05-26 IL IL266864A patent/IL266864A/en unknown
- 2019-06-25 US US16/451,333 patent/US11370818B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505622A5 (cg-RX-API-DMAC7.html) | ||
| JP2020500542A5 (cg-RX-API-DMAC7.html) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| JP2015508757A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537383A5 (cg-RX-API-DMAC7.html) | ||
| JP2012501670A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512838A5 (cg-RX-API-DMAC7.html) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| JP2011520898A5 (cg-RX-API-DMAC7.html) | ||
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| RU2016141919A (ru) | Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1) | |
| JP2018504105A5 (cg-RX-API-DMAC7.html) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2010526028A5 (cg-RX-API-DMAC7.html) | ||
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| JP2014500009A5 (cg-RX-API-DMAC7.html) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| RU2019115610A (ru) | Антитела и полипептиды, направленные против cd127 | |
| JP2013538057A5 (cg-RX-API-DMAC7.html) | ||
| JP2013506428A5 (cg-RX-API-DMAC7.html) |